Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
188 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Clostridium difficile Infections - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively. Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview 9 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 16 Products under Development by Universities/Institutes 20 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 21 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 29 Absynth Biologics Ltd 29 Actelion Ltd 29 AIMM Therapeutics BV 30 Akthelia Pharmaceuticals Ltd 30 AmpliPhi Biosciences Corp 31 Appili Therapeutics 31 Assembly Biosciences Inc 32 AvidBiotics Corp 32 C3J Therapeutics Inc 33 CaroGen Corp 33 Crestone Inc 34 Da Volterra SAS 34 Daiichi Sankyo Company Ltd 35 Evec Inc 35 GangaGen Inc 36 ImmunoBiology Ltd 36 Immuron Ltd 37 Inovio Pharmaceuticals Inc 37 Integrated BioTherapeutics Inc 38 Merck & Co Inc 38 MGB Biopharma Ltd 39 Microbiotix Inc 39 Micropharm Ltd 40 Miyarisan Pharmaceutical Company Ltd 40 Nabriva Therapeutics AG 41 Nanotherapeutics Inc 41 Novabiotics Ltd 42 NovoBiotic Pharmaceuticals LLC 42 Oragenics Inc 43 Otsuka Holdings Co Ltd 43 Pfizer Inc 44 Prokarium Ltd 44 Rebiotix Inc 45 Sanofi Pasteur SA 45 Second Genome Inc 46 Seres Therapeutics Inc 46 Serometrix LLC 47 Sorrento Therapeutics Inc 47 Summit Therapeutics Plc 48 Synthetic Biologics Inc 48 Valevia UK Ltd 49 Valneva SE 49 XBiotech Inc 50 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles 51 ABCD-01 - Drug Profile 51 ABIM-101 - Drug Profile 53 AKT-10081 - Drug Profile 54 Antibodies for Enterocolitis - Drug Profile 55 Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile 56 AvR2-V10 - Drug Profile 57 Biologic for Clostridium difficile Infections - Drug Profile 59 Biologics for Clostridium Difficile Infections - Drug Profile 60 cadazolid - Drug Profile 61 CBM-588 - Drug Profile 63 CD-17DL - Drug Profile 65 Cdiff Snare - Drug Profile 66 clofazimine - Drug Profile 67 Clostridium difficile (virus like particle) vaccine - Drug Profile 68 Clostridium difficile vaccine - Drug Profile 69 Clostridium difficile vaccine - Drug Profile 71 Clostridium difficile vaccine - Drug Profile 72 Clostridium difficile vaccine - Drug Profile 73 clostridium difficile vaccine - Drug Profile 75 Clostridium difficile vaccine - Drug Profile 76 Clostridium difficile vaccine - Drug Profile 77 Clostridium difficile vaccine - Drug Profile 78 Clostridium difficile vaccine - Drug Profile 79 Clostridium difficile vaccine - Drug Profile 80 CP-101 - Drug Profile 81 CRS-3123 - Drug Profile 82 DAV-132 - Drug Profile 83 DiffiKil - Drug Profile 84 Drugs for Clostridium difficile Infections - Drug Profile 85 DS-2969 - Drug Profile 86 EV-029104 - Drug Profile 87 EV-029105A - Drug Profile 88 fidaxomicin - Drug Profile 89 FIN-403 - Drug Profile 96 IMM-529 - Drug Profile 97 INS-5010 - Drug Profile 98 MBX-500 - Drug Profile 99 MCB-3681 - Drug Profile 101 MCB-3837 - Drug Profile 102 metronidazole - Drug Profile 103 MGBBP-3 - Drug Profile 104 Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile 107 Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile 108 Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 109 Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 110 Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 111 NP-432 - Drug Profile 112 OG-253 - Drug Profile 113 OG-716 - Drug Profile 115 OPS-2071 - Drug Profile 116 OraCAb - Drug Profile 117 P-100031 - Drug Profile 118 P-4A - Drug Profile 119 PF-06425090 - Drug Profile 120 PolyCAb - Drug Profile 122 Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 123 ramoplanin - Drug Profile 124 RBX-2660 - Drug Profile 125 RBX-7455 - Drug Profile 128 ribaxamase - Drug Profile 129 ridinilazole - Drug Profile 135 SER-109 - Drug Profile 141 SER-262 - Drug Profile 145 SHP-01 - Drug Profile 146 Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile 147 Small Molecules for Clostridium Difficile Infections - Drug Profile 148 Small Molecules for Clostridium Difficile Infections - Drug Profile 149 Small Molecules for Clostridium difficile Infections - Drug Profile 150 Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile 151 Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 152 Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 153 Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 154 Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile 155 Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 156 SQ-641 - Drug Profile 157 SYN-006 - Drug Profile 159 SYN-007 - Drug Profile 160 TNP-2092 - Drug Profile 161 VAL-301 - Drug Profile 162 VE-303 - Drug Profile 163 VLA-84 - Drug Profile 164 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 167 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 170 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 171 Featured News & Press Releases 171 Appendix 182 Methodology 182 Coverage 182 Secondary Research 182 Primary Research 182 Expert Panel Validation 182 Contact Us 182 Disclaimer 183
List of Tables
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
